Ignite Creation Date:
2024-05-06 @ 7:10 PM
Last Modification Date:
2024-10-26 @ 3:01 PM
Study NCT ID:
NCT05918913
Status:
AVAILABLE
Last Update Posted:
2024-06-24
First Post:
2023-06-15
Brief Title:
Expanded Access Program for Revumenib
Sponsor:
Syndax Pharmaceuticals
Organization:
Syndax Pharmaceuticals
Study Overview
Official Title:
Expanded Access Program for SNDX-5613 in Patients With RelapsedRefractory Acute Leukemias With Genetic Alterations Associated With HOXA Overexpression
Status:
AVAILABLE
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This expanded access program will provide an investigational treatment option in a controlled clinical setting for participants who are not otherwise eligible to participate in other Syndax-sponsored clinical studies and have no approved treatment options
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None